IP Library Granted Patent US 12,667,607
Granted Patent B2
US 12,667,607 · App. 18/315,351 · Granted Jun 30, 2026

Methods of reducing collagenase-mediated bruising in a subject having cellulite

Inventors: Saji Vijayan (Downingtown, PA); David Hernandez (Lititz, PA); James Patrick Tursi (Moorestown, NJ)
Assignee: Endo Operations Limited
A61K38/4886A61K9/0019A61P17/02A61P19/04C12Y304/24007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,667,607
App. No.
18/315,351
Filed
May 10, 2023
Granted
Jun 30, 2026
Kind
B2
Examiner
ARIANI, KADE
Art Unit
1651
USPC
424/94.67
Abstract

Disclosed herein are methods of reducing collagenase-mediated bruising in a subject having cellulite, methods of treating cellulite in a subject, and collagenase-containing formulations.

Claims (12)

1 . A method of reducing bruising and/or skin discoloration associated with collagenase-mediated treatment of cellulite in a subject, the method comprising:

subcutaneously administering to a treatment area of the subject a total dose of about 0.42 mg of collagenase per treatment session to thereby reduce the bruising and/or skin discoloration associated with the collagenase-mediated treatment of cellulite in the subject, wherein the subject experiences an at least 1 level improvement on an Investigator Assessment of Bruising Severity Scale (IABSS).

2 . The method of claim 1 , wherein the collagenase is administered using a three-injection technique.

3 . The method of claim 2 , wherein the collagenase is administered at a depth of about 0.5 inches.

4 . The method of claim 1 , wherein the collagenase has a concentration of about 0.23 mg/ml.

5 . The method of claim 1 , wherein the subject receives multiple treatment sessions.

6 . The method of claim 5 , wherein the treatment sessions are 3 weeks apart.

7 . The method of claim 1 , wherein the collagenase is administered in a composition comprising the collagenase, mannitol, sucrose, and tromethamine.

8 . The method of claim 1 , wherein the collagenase comprises a collagenase I, a collagenase II, or a mixture of collagenase I and collagenase II.

9 . The method of claim 8 , wherein the collagenase comprises the mixture of collagenase I and collagenase II.

10 . The method of claim 9 , wherein the collagenase I comprises the amino acid sequence of SEQ ID NO: 1 and the collagenase II comprises the amino acid sequence of SEQ ID NO: 2.

11 . The method of claim 8 , wherein the collagenase is collagenase Clostridium histolyticum (CCH).

Assignments (7)
SECURITY INTEREST Recorded Aug 3, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: GOLDMAN SACHS BANK USA
Reel/Frame 075503/0036 →
SECURITY INTEREST Recorded Aug 3, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 075503/0049 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT APPLICATION NUMBER 18/315,521 WITH CORRECT PATENT APPLICATION NUMBER 18/315,351 PREVIOUSLY RECORDED ON REEL 67198 FRAME 598. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded Apr 17, 2025
From: ENDO GLOBAL AESTHETICS LIMITED
To: PALADIN PHARMA INC.
Reel/Frame 070887/0742 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER PREVIOUSLY RECORDED AT REEL: 67245 FRAME: 714. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 17, 2025
From: PALADIN PHARMA INC.
To: ENDO OPERATIONS LIMITED
Reel/Frame 070887/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2024
From: PALADIN PHARMA INC.
To: ENDO OPERATIONS LIMITED
Reel/Frame 067245/0714 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2024
From: ENDO GLOBAL AESTHETICS LIMITED
To: PALADIN PHARMA INC.
Reel/Frame 067198/0598 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2023
From: VIJAYAN, SAJI; HERNANDEZ, DAVID; TURSI, JAMES PATRICK
To: ENDO GLOBAL AESTHETICS LIMITED
Reel/Frame 064439/0664 →
Continuity (3)
Provisional Application 63378424 · Oct 5, 2022
Provisional Application 63340295 · May 10, 2022
Related Publication 20230405097A1 · Dec 21, 2023
References Cited (16)
US 7374551B2 · Liang et al. · 2008 [cited by applicant]
US 7811560B2 · Sabatino et al. · 2010 [cited by applicant]
US 9744138B2 · Leppert et al. · 2017 [cited by applicant]
US 9757435B2 · Herber · 2017 [cited by applicant]
WO 2007100675A2 · 2007 [cited by applicant]
WO 2012125948A1 · 2012 [cited by applicant]
WO 2020021330A2 · 2020 [cited by applicant]
WO 2020021332A2 · 2020 [cited by applicant]
WO 2020058755A1 · 2020 [cited by applicant]
Auxilium Press release , Exhibit 99.1, 2011, p. 1-4. (Year: 2011). [cited by examiner]
Goldman et al., “Phase 2a, randomized, double-blind, placebo-controlled dose-ranging study of repeat doses of collagenase clostridium histolyticum for the treatment of edematous fibrosclerotic panniculopathy (cellulite)… [cited by applicant]
Hexsel et al., “A validated photonumeric cellulite severity scale”, Journal of the European Academy of Dermatology and Venereology, Feb. 2009, 7 pages. [cited by applicant]
Kaufman-Janette et al., “Collagenase Clostridium Histolyticum-aaes for the Treatment of Cellulite in Women: Results From Two Phase 3 Randomized, Placebo-Controlled Trials”, Dermatol. Surg. 2021, 47(5), 649-656. [cited by applicant]
Nurnberger et al., “So-Called Cellulite: An Invented Disease”, J. Dermatology Surgery Oncol., Mar. 1978, 221-229. [cited by applicant]
Qwo® (collagenase clostridium histolyticum-aaes) for injection, Package insert, Endo Aesthetics LLC, 2020, 11 pages. [cited by applicant]
Shridharani, Presented at: Vegas Cosmetic Surgery and Aesthetic Dermatology, Sep. 24-27, 2020, Virtual. [cited by applicant]